贵州百灵：全资子公司获得药物临床试验批准通知书

Core Points - Guizhou Bailing announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for clinical trials of Tangning Tongluo tablets for the treatment of type 2 diabetes [2] Company Summary - The clinical trial approval is significant for Bailing Yuxiu as it allows the company to advance its research and development efforts in diabetes treatment [2] - The approved clinical trial is expected to enhance the company's product portfolio and potentially increase its market share in the diabetes medication sector [2]